FDA Approves Allergan’s Drug for Longer Eyelashes
Allergan Inc, maker of Botox, said on Friday that the U.S. Food and Drug Administration has approved its eyelash-thickening drug Latisse.
Excerpt from:
FDA Approves Allergan’s Drug for Longer Eyelashes
Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse — First and Only Treatment Approved by the FDA for Hypotrichosis of…
IRVINE, Calif.–(BUSINESS WIRE)–Dec 26, 2008 – Allergan, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved Latisse (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes.
FDA OKs 1st Eyelash Drug Latisse
Title: FDA OKs 1st Eyelash Drug LatisseCategory: Health NewsCreated: 12/29/2008Last Editorial Review: 12/29/2008 (Source: MedicineNet Eyesight General) MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network , and receive $5 free advertising.
Go here to see the original:
FDA OKs 1st Eyelash Drug Latisse
FDA OKs Latisse For Hypotrichosis of Eyelashes Treatment
New prescription drug Latisse increases the length, thickness and darkness of eyelashes. (Source: Huliq Health News)
Excerpt from:
FDA OKs Latisse For Hypotrichosis of Eyelashes Treatment
Allergan Eyelash Enhancer Approved
Allergan received FDA approval to market Latisse, a beauty treatment that increases the length, thickness and darkness of eyelashes by using a drug the company developed to treat glaucoma. (Source: WSJ.com: Health)
Original post:
Allergan Eyelash Enhancer Approved
Allergan Gets Nod For Eyelash Treatment
Eye care and cosmetic drug maker Allergan on Friday said its eyelash growth treatment Latisse received Food and Drug Administration approval,… (Source: Investor’s Business Daily: HEALTH)
See the original post here:
Allergan Gets Nod For Eyelash Treatment
(sponsored multimedia) Latisse™ (bimatoprost ophthalmic solution) 0.03%: A National Summit on New Aesthetic Opportunities
(Source: Modern Medicine)
See the original post:
(sponsored multimedia) Latisse™ (bimatoprost ophthalmic solution) 0.03%: A National Summit on
New Aesthetic Opportunities
FDA Advisory Committee Unanimously Recommends Approval of Latisse (Bimatoprost Solution 0.03%) as a Treatment for Hypotrichosis of Eyelashes
IRVINE, Calif.–(BUSINESS WIRE)–Dec 5, 2008 – Allergan, Inc. today announced the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted unanimously (9-0) to recommend that the FDA approve Latisse…
